AXSM vs. NVO
AXSM (Axsome Therapeutics, Inc.) and NVO (Novo Nordisk A/S) are both stocks. Both are in the Healthcare sector — AXSM in Biotechnology, NVO in Drug Manufacturers - General. Over the past 10 years, AXSM returned 42.66%/yr vs 8.27%/yr for NVO. At a 0.15 correlation, their price movements are largely independent.
Performance
AXSM vs. NVO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, AXSM achieves a 35.70% return, which is significantly higher than NVO's -6.67% return. Over the past 10 years, AXSM has outperformed NVO with an annualized return of 42.66%, while NVO has yielded a comparatively lower 8.27% annualized return.
AXSM
- 1D
- -1.06%
- 1M
- 5.03%
- YTD
- 35.70%
- 6M
- 60.21%
- 1Y
- 146.15%
- 3Y*
- 41.16%
- 5Y*
- 28.89%
- 10Y*
- 42.66%
NVO
- 1D
- 6.23%
- 1M
- 2.05%
- YTD
- -6.67%
- 6M
- -1.28%
- 1Y
- -34.91%
- 3Y*
- -14.58%
- 5Y*
- 4.55%
- 10Y*
- 8.27%
AXSM vs. NVO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
AXSM Axsome Therapeutics, Inc. | 35.70% | 115.86% | 6.31% | 3.19% | 104.16% | -53.63% | -21.18% | 3,565.25% | -49.64% | -17.04% |
NVO Novo Nordisk A/S | -6.67% | -39.22% | -15.93% | 54.84% | 22.66% | 63.52% | 23.33% | 28.70% | -12.98% | 52.92% |
Correlation
The correlation between AXSM and NVO is 0.17, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.17 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.16 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.18 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.15 |
Correlation (All Time) Calculated using the full available price history since Nov 19, 2015 | 0.15 |
Fundamentals
AXSM:
$12.69B
NVO:
$204.11B
AXSM:
-$3.74
NVO:
DKK 27.42
AXSM:
17.61
NVO:
4.06
AXSM:
232.46
NVO:
6.55
AXSM:
$708.24M
NVO:
DKK 327.80B
AXSM:
$655.82M
NVO:
DKK 268.30B
AXSM:
-$172.72M
NVO:
DKK 181.54B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
AXSM vs. NVO — Risk / Return Rank
AXSM
NVO
AXSM vs. NVO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Axsome Therapeutics, Inc. (AXSM) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| AXSM | NVO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +4.20 | ||
| Sortino ratioReturn per unit of downside risk | +5.62 | ||
| Omega ratioGain probability vs. loss probability | 1.59 | 0.90 | +0.70 |
| Calmar ratioReturn relative to maximum drawdown | 7.95 | -0.71 | +8.66 |
| Martin ratioReturn relative to average drawdown | 23.42 | -1.13 | +24.55 |
Loading charts...
Drawdowns
AXSM vs. NVO - Drawdown Comparison
The maximum AXSM drawdown since its inception was -86.65%, which is greater than NVO's maximum drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for AXSM and NVO.
Loading charts...
Drawdown Indicators
| AXSM | NVO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -86.65% | -74.70% | -11.95% |
Max Drawdown (1Y)Largest decline over 1 year | -18.50% | -49.17% | +30.67% |
Max Drawdown (3Y)Largest decline over 3 years | -34.83% | -74.70% | +39.87% |
Max Drawdown (5Y)Largest decline over 5 years | -72.91% | -74.70% | +1.79% |
Max Drawdown (10Y)Largest decline over 10 years | -81.26% | -74.70% | -6.56% |
Current DrawdownCurrent decline from peak | -2.87% | -66.66% | +63.79% |
Average DrawdownAverage peak-to-trough decline | -39.40% | -17.81% | -21.59% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.27% | 32.54% | -26.27% |
Volatility
AXSM vs. NVO - Volatility Comparison
The current volatility for Axsome Therapeutics, Inc. (AXSM) is 8.92%, while Novo Nordisk A/S (NVO) has a volatility of 11.74%. This indicates that AXSM experiences smaller price fluctuations and is considered to be less risky than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| AXSM | NVO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.92% | 11.74% | -2.82% |
Volatility (6M)Calculated over the trailing 6-month period | 33.16% | 38.27% | -5.11% |
Volatility (1Y)Calculated over the trailing 1-year period | 41.74% | 52.05% | -10.31% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 70.26% | 38.45% | +31.81% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 90.40% | 32.60% | +57.80% |
Dividends
AXSM vs. NVO - Dividend Comparison
AXSM has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 3.93%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
AXSM Axsome Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
NVO Novo Nordisk A/S | 3.93% | 3.31% | 1.68% | 1.00% | 1.20% | 1.35% | 1.87% | 2.14% | 1.45% | 1.52% | 2.87% | 0.92% |
Financials
AXSM vs. NVO - Financials Comparison
This section allows you to compare key financial metrics between Axsome Therapeutics, Inc. and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
AXSM vs. NVO - Profitability Comparison
AXSM - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Axsome Therapeutics, Inc. reported a gross profit of 176.48M and revenue of 191.20M. Therefore, the gross margin over that period was 92.3%.
NVO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a gross profit of 83.23B and revenue of 96.82B. Therefore, the gross margin over that period was 86.0%.
AXSM - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Axsome Therapeutics, Inc. reported an operating income of -63.36M and revenue of 191.20M, resulting in an operating margin of -33.1%.
NVO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported an operating income of 59.62B and revenue of 96.82B, resulting in an operating margin of 61.6%.
AXSM - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Axsome Therapeutics, Inc. reported a net income of -64.54M and revenue of 191.20M, resulting in a net margin of -33.8%.
NVO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a net income of 48.56B and revenue of 96.82B, resulting in a net margin of 50.2%.
Frequently Asked Questions
AXSM and NVO have a correlation of 0.17, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NVO has higher volatility (11.74%) compared to AXSM (8.92%). In terms of maximum drawdown, AXSM dropped -86.65% vs NVO's -74.70%.
AXSM currently has the higher Sharpe Ratio (3.53 vs -0.67), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for AXSM and NVO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer